中金发表研报指，百济神州(06160.HK) (BGNE.US)2024财年收入38.1亿美元(下同)，其中产品收入37.8亿元，归母净亏损6.4亿元，业绩略胜该行预期。公司管理层指引2025财年有望实现收入介乎49至53亿元，并实现通用会计准则经营利润转正，经营活动产生正现金流，同样超出该行预期。
中金表示，由于泽布替尼放量超预期，故上调百济神州2025财年盈利预测由亏损1.01亿元至盈利0.53亿元，上调2026财年盈利预测10%至4.05亿元。该行将百济神州H股目标价上调7.6%至198港元；美股目标价上调7.8%至332美元，维持“跑赢行业”评级。(js/a)(港股报价延迟最少十五分钟。沽空资料截至 2025-02-28 16:25。) (美股为即时串流报价； OTC市场股票除外，资料延迟最少15分钟。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.